BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jul. 17, 2024 |
Mar. 31, 2025 |
Mar. 31, 2025 |
Mar. 31, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Product Information [Line Items] | ||||||
| Net Cash Provided by (Used in) Operating Activities | $ (455,198) | $ (351,458) | ||||
| Stock Issued During Period, Value, Issued for Services | $ 60,000,000 | $ 4,688 | 4,688 | 9,482 | ||
| Stock Issued During Period, Value, New Issues | 1,500,000 | 128,000 | ||||
| Cash on hand | 3,265,100 | 3,265,100 | ||||
| Inventory, Net | $ 21,198 | 21,198 | ||||
| Research and development costs | $ 119,281 | 57,447 | ||||
| Warrant [Member] | ||||||
| Product Information [Line Items] | ||||||
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 6,250,000 | 6,250,000 | 18,797,000 | |||
| Stock Issued During Period, Value, New Issues | $ 6,250 | |||||
| Common Stock [Member] | ||||||
| Product Information [Line Items] | ||||||
| Stock Issued During Period, Value, Issued for Services | 38 | 140 | ||||
| Number of common stock shares issued, value | $ 1,500,000 | $ 2,266,000 | ||||
| Sale of Stock, Number of Shares Issued in Transaction | 12,500,000 | 24,950,000 | ||||
| Stock Issued During Period, Value, New Issues | $ 12,500 | $ 2,000 | ||||
| Private Placement [Member] | ||||||
| Product Information [Line Items] | ||||||
| Number of common stock shares issued, value | $ 1,179,245 | |||||
| Sale of Stock, Number of Shares Issued in Transaction | 16,132,000 | |||||
| Radionuclide Therapy Product Line [Member] | ||||||
| Product Information [Line Items] | ||||||
| Net Cash Provided by (Used in) Operating Activities | $ 3,000,000.0 | $ 2,500,000 | ||||
| Offering term | Over the next 36 months, the Company believes it will require approximately $9.0 million in additional capital to: (i) fund the FDA approval process to conduct human clinical trials; (ii) conduct Phase I, pilot, clinical trials; (iii) activate several regional clinics to administer IsoPet® across the U.S.; (iv) create an independent production center within the current production site to create a template for future international manufacturing; and (v) initiate regulatory approval processes outside of the U.S. | |||||